Recent Updates
Recently added Catalysts
AKTX

Akari Therapeutics Plc (Nasdaq: AKTX) to Ring the Nasdaq Stock Market Opening Bell

Key Takeaway: ADVISORY, Dec. 04, 2015 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq:AKTX), an emerging growth, development-stage biopharmaceutical company focused on orphan and rare autoimmune and inflammatory diseases, will visit the Nasdaq MarketSite in Times Square. In honor of the o

Full Press Release Details

ADVISORY, Dec. 04, 2015 (GLOBE NEWSWIRE) --
Akari Therapeutics Plc (Nasdaq:AKTX), an emerging growth, development-stage biopharmaceutical company focused on orphan and rare autoimmune and inflammatory diseases, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Dr. Gur Roshwalb, Chief Executive Officer will ring the Opening Bell.
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Monday, December 7, 2015 – 9:15 a.m. to 9:30 a.m. ET
Akari Therapeutics Plc Media Contact:
Gur Roshwalb, MD, CEO
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For photos from ceremonies and events visit our Instagram Page:
For news tweets, please visit our Twitter page at:
For exciting viral content and ceremony photos visit Tumblr Page:
A webcast of the Nasdaq Opening Bell will be available at:
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Akari Therapeutics Plc (Nasdaq:AKTX):
Akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan and rare autoimmune and inflammatory diseases. Akari’s lead drug, Coversin is a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b-9 (also known as the membrane attack complex or MAC). C5 inhibition is growing in importance in a range of rare autoimmune diseases related to dysregulation of the complement component of the immune system, including paroxysmal nocturnal hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS), and Guillain Barré syndrome (GBS).
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,600 listed companies with a market value of approximately $8.8 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

Tags

Last updated: Dec 4, 2015